Researchers from the Baylor College of Medicine have characterized 100 conserved Alzheimer’s disease (AD) risk orthologue ...

Engene Holdings Inc.’s protocol amendment to its phase II trial with detalimogene voraplasmid in bladder cancer worked out in ...

There is evidence that NACHT, LRR and PYD domains-containing protein 3 (NLRP3)-driven mechanisms may drive both peripheral and hypothalamic inflammation in preclinical obesity. NLRP3 inflammasome ...

Evotec SE has received a $5 million milestone payment from Bristol Myers Squibb Co. (BMS), following the acceptance of an IND application by the FDA in the companies’ strategic protein degradation ...

At first glance, the results of the CLOSURE-AF study would seem to spell doom for left atrial appendage closure devices for patients at risk of stroke, but there is some noise in the signal, including ...

SPT Labtech Ltd. recently partnered with Alithea Genomics SA to integrate its firefly liquid handling platform with Alithea’s ...

The industry has been complaining about the drug pricing and reimbursement policies of European governments for years, but ...

Patients and their doctors are no fans of long-term use of direct oral anticoagulants (DOACs) after ablation treatment for ...

Biopharma financings from January through October 2025 totaled $61.45 billion, roughly in line with the $61.04 billion raised ...

Takeda Pharmaceutical Co. Ltd.’s anti-CD38 antibody, mezagitamab (TAK-079), sustained kidney function up to 18 months after ...

Bluejay Therapeutics Inc.’s lead compound, the fully human monoclonal antibody brelovitug (BJT-778), produced positive virologic response data in the company’s phase II study of chronic hepatitis D ...

The U.K. government has published a road map for phasing out animal testing in life sciences research and announced £75 ...